GILEAD
Creating Possible

Innovation for Sustainable Growth

J.P. Morgan Healthcare Conference

10 January 2022

Forward Looking Statements

Statements included in this presentation that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: the impact of the COVID-19 pandemic on Gilead's business, financial condition and results of operations; the development, manufacturing and distribution of Veklury as a treatment for COVID-19, including the uncertainty of the amount and timing of future Veklury sales and Gilead's ability to effectively manage the global supply and distribution of Veklury; Gilead's ability to achieve its anticipated full year 2021 financial results, including as a result of potential adverse revenue impacts from COVID-19, increases in R&D expenses and potential revenues from Veklury; Gilead's ability to make progress on any of its long-term ambitions or strategic priorities laid out in its corporate strategy; Gilead's ability to accelerate or sustain revenues for its virology, oncology and other programs; Gilead's ability to realize the potential benefits of acquisitions, collaborations or licensing arrangements; Gilead's ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, and the possibility of unfavorable results from ongoing and additional clinical trials; the risk that safety and efficacy data from clinical studies may not warrant further development of Gilead's product candidates or the product candidates of Gilead's strategic partners; Gilead's ability to submit new drug applications for new product candidates in the currently anticipated timelines; Gilead's ability to receive regulatory approvals in a timely manner or at all, and the risk that any such approvals may be subject to significant limitations on use; Gilead's ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead's products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of these products over other therapies and may therefore be reluctant to prescribe the products; and other risks identified from time to time in Gilead's reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements.

The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.

Gilead Today: Accelerating Path to Sustainable Growth

2019

- Stabilized post-HCV decline
- Virology >90% of revenue
- Oncology <5% of revenue
- Transitioned leadership and strategy

TODAY

- **Growing HIV revenues**
- **Executing on oncology strategy, tracking to exceed $1B in revenue**
- **Nearly doubled clinical pipeline**
- **Key role in helping to combat COVID**

2030

- Expanding virology leadership: expect stable or growing HIV business
- Delivering a world-class oncology portfolio: expect to be a third of revenues
- Targeting 10+ transformative therapies by 2030

Expanding Virology Leadership Across Portfolio

VIRAL HEPATITIS[1]

$2.2B

Q321 YTD SALES

HCV Market Share
~60% in U.S. and ~50% in EU[3]

First Conditionally Approved Treatment in EU for HDV

HIV[2]

$11.8B

Q321 YTD SALES

Biktarvy #1 Prescribed Treatment in U.S.

~75% HIV Tx Market Share in U.S.

Descovy Maintains ~45% PrEP Market Share

EMERGING VIROLOGY

$4.2B

Q321 YTD SALES

Veklury as Standard of Care for Hospitalized Patients

First FDA Approved Treatment for COVID-19

Note: Q321 YTD reflects Q1–Q3 2021 performance. Biktarvy (bictegravir 50 mg, emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. Descovy (emtricitabine 200 mg, tenofovir alafenamide 25 mg) tablets. Veklury (remdesivir) 100 mg for injection. [1] Viral Hepatitis portfolio includes HCV, HBV and HDV. [2] HIV - Human immunodeficiency virus. Tx – Treatment. PrEP – Pre-exposure prophylaxis. [3] As of Q3 2021. U.S. Sources: IQVIA, Integrichain, New Patient Starts excludes PAP. Reflects EU5 Sources: Country Q3 EU5 and internal data.

HIV Franchise Well-Positioned For Growth

TREATMENT

- $6B Biktarvy Q321 YTD sales; 17% YoY growth
- Biktarvy patent expiration in 2033[1]
- Future long-acting options to sustain HIV business

~75%

On GILD-based Tx regimen in 2021[2]

+

PREVENTION

- Market back to growth
- Only ~20% penetrated today in U.S.[2]
- Future long-acting options to potentially catalyze PrEP market growth in mid-2020s

~45%

On Descovy for PrEP in 2021[3]

Note: Q321 YTD reflects Q1–Q3 2021 performance. YoY – Year-over-year growth for Q1-Q3 2021 vs Q1-Q3 2020. [1] Estimated patent expiry corresponds to the latest expiring compound patent for one of the active ingredients in the single tablet regimen. [2] Reflects HIV treatment regimen market share in the U.S. Source: IQVIA NPA MD Regimen Market (NRTI Market, excl. PrEP + 2-Drug Combos. [3] Reflects HIV PrEP regimen market share in the U.S. Source: Weekly IQVIA NPA/NSP

HIV: Sustainable Revenue Through 2030 and Beyond

Evolution of Gilead's HIV business

Biktarvy growth expected to continue **at least through mid-2020s**

Lenacapavir's potential 6-month dosing transforms PrEP market **starting in mid-2020s**

Gilead's multiple long-acting options to **launch and reshape** treatment market after 2027

Dynamics to Manage

- Long-acting competition
- Descovy LOE

Note: LOE – Loss of exclusivity. PrEP - Pre-exposure prophylaxis.

Targeting HIV Lifecycle With Long-Acting Portfolio



1

GS-2872 + GS-5423
Class: bNAb
Phase: 1b

bNAb
Class: bNAb
Phase: Exploratory

2

Islatravir[1]
Class: NRTI
Phase: 2

GS-5894
Class: NNRTI
Phase: 1

GS-1614
Class: NRTI
Phase: Pre-IND

LA Tenofovir
Class: NRTI
Phase: Discovery

3 **5**

Lenacapavir
Class: CAI
Phase: 2-3, NDA

GS-4182
Class: CAI
Phase: Pre-IND

Multiple Capsid Programs
Class: CAI
Phase: Discovery

4

LA Bictegravir
Class: INSTI
Phase: 1

GS-6212
Class: INSTI
Phase: Pre-IND

GS-1720
Class: INSTI
Phase: Pre-IND

INSTI
Class: INSTI
Phase: Discovery

6

GS-1156
Class: PI
Phase: Discovery

[1] Merck's investigational islatravir. Note: bNAb - Broadly neutralizing antibody; CAI - Capsid assembly inhibitor; IND - Investigational new drug; INSTI - Integrase strand transfer inhibitor; LA - Long-acting; NDA - New drug application; NRTI - Nucleoside reverse transcriptase inhibitor; NNRTI - Non-nucleoside reverse transcriptase inhibitor; PI - Protease inhibitor.

Long-Acting Pipeline Positioned To Be Best-in-Disease

Treatment

Dosing Every	Foundation	Partner
1 Week	Lenacapavir	NNRTI, Phase 1
1 Week	Lenacapavir	Islatravir[1], Phase 2
1-3 Months	Lenacapavir	LA Bictegravir, Phase 1
3 Months	Lenacapavir	Islatravir, IND TBD
6 Months	Lenacapavir	2 bNAbs, Phase 1b POC

Prevention

Dosing Every	Foundation	
6 Months	Lenacapavir	PURPOSE 1 and 2, Phase 3

Potential Approval in **2025**

"With 6-month dosing, if approved, lenacapavir would have the potential to be a true game changer."

-- Monica Gandhi, MD, MPH; Professor of Medicine, Division of HIV, Infectious Disease and Global Medicine, UCSF; Director: UCSF Center for AIDS Research

Note: Lenacapavir is an investigational agent and is not approved by any regulatory authority for any use; it's safety and efficacy are not established. Merck's islatravir is an investigational agent and is not approved by any regulatory authority for any use; it's safety and efficacy are not established. [1] FDA has placed a partial clinical hold on the Phase 2 long-acting oral trial of lenacapavir and Merck's islatravir.

Presented strong lenacapavir 6-month efficacy data for HTE population; NDA submitted.

Applying Antiviral Expertise to COVID-19 and Beyond

Veklury® remdesivir

87%

Reduction in risk for hospitalization in investigational PINETREE study[1]

3 in 5

Hospitalized COVID-19 patients in U.S. receive Veklury[2]

~10M

Patients treated globally[3]

127

Countries with distribution access[4]

Growth of Virology Pipeline

- HIV cure / remission
- Viral Hepatitis
- Respiratory Viruses
- Pandemic / Emerging Viruses
- Herpesviruses

Oral COVID-19 remdesivir pro-drug IND cleared with Phase 1 initiation expected in Q122.

[1] Veklury demonstrated a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by Day 28 compared with placebo; no deaths occurred in either arm of the study through the primary endpoint. Results from Phase 3 PINETREE Study in non-hospitalized patients at high risk of disease progression. Source: Gottleib et al (NEJM 2021). In the U.S., the use of Veklury for non-hospitalized patients is investigational; this use has not been approved by the U.S. FDA. [2] Hospitalized patients treated and utilization estimates are based on global Veklury, global remdesivir, and generic remdesivir volume donated and shipped for distribution. [3] Patients treated and utilization estimates are based on global Veklury, global remdesivir, and generic remdesivir volume donated and shipped for distribution. Within the US, assumed average treatment course is 5.5 vials/patient and ex-US, assumed average treatment course is 6.25 vials/patient. [4] Countries with distribution access is through voluntary licensing.

Oncology Revenue Growing to Exceed $1B in 2021

YESCARTA® TECARTUS®

- 97% manufacturing reliability
- ~42% YoY[1] growth

$632M
Q321 YTD SALES[2]

Key Anticipated Milestones

Kite, A GILEAD Company

- 2L LBCL sBLA decision in 1H22, MAA in 2H22
- ALL and iNHL MAA decisions in 2022
- Maryland manufacturing site online mid-2022

TRODELVY™

- Launched in 2L mTNBC and 2L mUC
- 2L mTNBC new patient starts increased to 1 in 4[3]

$262M
Q321 YTD SALES[2]

Key Anticipated Milestones

- TROPiCS-02 HR+/HER2- readout in Q122
- 15+ new trials planned in 2022
- Includes 7+ new Phase 3 trials in 2022

Note: Yescarta (axicabtagene ciloleucel) for IV infusion, Tecartus (brexucabtagene autoleucel) for IV infusion, and Trodelvy (sacituzumab govitecan-hziy) for injection. ALL - acute lymphocytic leukemia. FL - follicular lymphoma. LBCL - large B cell lymphoma. sBLA – Supplemental biologics license application. MAA – Marketing authorization application. mTNBC – Metastatic triple negative breast cancer. FDA approval received for 2L mTNBC in April 2021, followed by approvals in EU, Switzerland, Canada, Australia, and Great Britain. FDA granted accelerated approval for 2L mUC in April 2021. [1] YoY – Year-over-year growth for Q1-Q3 2021 vs Q1-Q3 2020. [2] Q321 YTD reflects Q1-Q3 2021 performance. [3] Source: IQVIA. This information is an estimate derived from the use of information under license from the following IQVIA information service: LAAD claims for the period October 2021. IQVIA expressly reserves all rights, including rights of copying, distribution and republication.

Delivering a World-Class Oncology Portfolio

Today

18
Oncology Assets

>30
Oncology Clinical Trials

13
New Clinical Trial Initiations in 2021

Establishing Robust Portfolio

- Portfolio rich with opportunities for combinations
- Doubled the talent dedicated to oncology[1]

By 2030

- ✓ Clear pathway to deliver **20+ transformative indication approvals**
- ✓ **Positively impact 400,000+ patient lives**
- ✓ Expect oncology to be **at least a third** of total revenues

[1] Compares EOY 2021 vs EOY 2019. Oncology talent includes fully dedicated headcount in commercial SG&A, R&D and manufacturing since EOY 2019.

Oncology Scientific Framework Shaping Pipeline

Trigger Tumor-Intrinsic Cell Death

Antibody-Drug Conjugate

- **TROP2**
  Trodelvy

Tumor Cell Apoptosis

- **MCL-1**
  GS-9716

Promote Immune-Mediated Tumor-Killing

T & NK Cell Checkpoint and Co-Stimulation

- **TIGIT**
  domvanalimab & AB308
- **PD-1**
  zimberelimab
- **HLA-G**
  TTX-080
- **CD137**
  AGEN2373

Engineered T-cells

- **CD19 CAR-T**
  Yescarta
- **CD19 CAR-T**
  Tecartus
- **CD19/20 CAR-T**
  KITE-363
- **CLL1 CAR-T**
  KITE-222

Macrophage-Mediated Phagocytosis

- **CD47**
  magrolimab
- **SIRPα**
  GS-0189

T-cell Priming & Diff.

- **FLT3R** | GS-3583



Remodel Tumor-Permissive Microenvironment

Macrophage-Mediated Immuno-Suppression

- **TREM1**
  PY-159
- **TREM2**
  PY-314

Adenosine-Mediated Immuno-Suppression

- **$A_{2A}R/A_{2B}R$**
  etrumadenant
- **CD73**
  quemliclustat

Treg-Mediated Immuno Suppression

- **CCR8**
  GS-1811

Note: Gilead and Arcus will co-develop and co-commercialize domvanalimab and AB308, zimberelimab, etrumadenant, and quemliclustat. Gilead has the exclusive rights to develop and commercialize Jounce's anti-CCR8 antibody, referred to as GS-1811. Gilead has exclusive options to acquire Tizona, including its TTX-080, and Pionyr, including its PY-159 and PY-314. Gilead has the exclusive rights to opt-in for Agenus' AGEN2373.

Combination Potential For Novel Oncology Portfolio

Trigger Tumor-Intrinsic Cell Death

TROP2
Trodelvy

MCL1
GS-9716

Promote Immune-Mediated Tumor-Killing

CD47
magrolimab

CD19
Yescarta/
Tecartus

CD19/20
KITE-363

CLL1
KITE-222

TIGIT
domvanalimab
& AB308

FLT3R
GS-3583

HLA-G
TTX-080

PD-1
zimberelimab

SIRPα
GS-0189

CD137
AGEN2373

Remodel Tumor-Permissive Microenvironment

$A_{2A}R/A_{2B}R$
etrumadenant

CD73
quemliclustat

CCR8
GS-1811

TREM1
PY-159

TREM2
PY-314

Active and Potential Combinations[1]



TIGIT
domvanalimab

PD-1
zimberelimab

$A_{2A}R/A_{2B}R$
etrumadenant



TROP2
Trodelvy

PD-1
Keytruda



CCR8
GS-1811

PD-1
zimberelimab



TROP2
Trodelvy

CD47
magrolimab

Note: Gilead and Arcus will co-develop and co-commercialize domvanalimab and AB308, zimberelimab, etrumadenant, and quemliclustat. Gilead has the exclusive rights to develop and commercialize Jounce's anti-CCR8 antibody, referred to as GS-1811. Gilead has exclusive options to acquire Tizona, including its TTX-080, and Pionyr, including its PY-159 and PY-314. Gilead has the exclusive rights to opt-in for Agenus' AGEN2373. [1] Actively explored combinations: domvanalimab + zimberelimab + etrumadenant; Trodelvy + Keytruda. Potential combinations to explore: GS-188 + zimberelimab; Trodelvy + magrolimab.

Expanding Across Breadth of Indications

Solid Tumors[1]

Triple-Negative Breast Cancer	Bladder Cancer	HR+ / HER2- Breast Cancer	Non-Small Cell Lung Cancer	Head and Neck Cancer
Prostate Cancer	Pancreatic Cancer	Colorectal Cancer	Endometrial Cancer	Small Cell Lung Cancer
Gastric and Gastroesophageal Junction Cancer	Cervical Cancer	Ovarian Cancer	Renal Cell Carcinoma	

Hematological Cancers[2]

Large B-cell Lymphoma	Follicular Lymphoma	Acute Lymphocytic Leukemia
Mantle Cell Lymphoma	Acute Myeloid Leukemia	Myelodysplastic Syndrome
Multiple Myeloma	Chronic Lymphocytic Leukemia	

● Approved or Accelerated Approval Indication ● In Clinical Programs ● Potential Indications for Exploration

Select Partnerships:

agenus · APPIA BIO · ARCUS BIOSCIENCES · Jounce THERAPEUTICS · MERCK · PIONYR IMMUNOTHERAPEUTICS · SHORELINE biosciences · TIZONA THERAPEUTICS

[1]Trodelvy received full approval for 2L metastatic triple-negative breast cancer in the US, EU, and Project Orbis countries; Trodelvy received accelerated approval for 2L metastatic urothelial cancer in the US. [2] Yescarta is approved for 3L+ relapsed/refractory (R/R) large B-cell lymphoma in the US and EU, among others, and received accelerated approval in 3L+ R/R follicular lymphoma in the US. Tecartus was granted accelerated approval for R/R mantle cell lymphoma in the US and EU, and full approval for R/R adult acute lymphoblastic leukemia.

Strong Oncology Pipeline Execution and Expansion

>30

clinical trials today

- **13 new trial starts in 2021**
- **4 with Breakthrough Therapy Designation**
  - Trodelvy 2L mTNBC
  - Magrolimab 1L HR MDS
  - Yescarta r/r FL
  - Tecartus adult ALL
- **4 Approvals in 2021**
  - Trodelvy in 2L mTNBC
  - Tecartus in adult ALL
  - Trodelvy in 2L mUC (accelerated)
  - Yescarta in r/r FL (accelerated)

>20

new trials planned to initiate in 2022

(Includes Gilead-sponsored or partnered / co-developed studies expected to start in 2022)

Sacituzumab govitecan-hziy Trodelvy TROP2	*Approved*	*2L mTNBC*
	Approved	*2L mUC*
	Ph3	*HR+/HER2- mBC*
	Ph3	*2-3L NSCLC*
	Ph2	*Solid Tumor Basket*
MERCK	*Ph3*	*1L mTNBC*
	Ph3	*1L mTNBC*
	Ph3	*Breast*
	Ph3	*Breast*
	Ph3	*Bladder*
	Ph3	*Bladder*
MERCK	*Ph3*	*1L NSCLC*
MERCK	*Ph2*	*1L NSCLC*
	Ph2	*Bladder*
	Ph2	*Bladder*
	Ph2	*Colorectal*
	Ph2	*Lung*
	Ph2	*Pancreatic*
	Ph2	*Prostate*

Domvanalimab TIGIT AstraZeneca	*Ph3*	*1L NSCLC*
	Ph2	*1L NSCLC*
	Ph3	*Stage 3 NSCLC*
	Ph3	*Lung*
	Ph3	*GI*
	Ph3	*TBD*
Magrolimab CD47	*Ph3*	*1L HR MDS*
	Ph3	*1L AML*
	Ph3	*1L Unfit AML*
	Ph2	*HNSCC*
	Ph2	*MM*
	Ph2	*Solid Tumors*
	Ph2	*TNBC*
	Ph2	*DLBCL*
	Ph2	*Colorectal*
	Ph1/2	*TBD*

Legend: Active | Planned

Note: ALL - Acute lymphocytic leukemia. AML - Acute myeloid leukemia. DLBCL – Diffuse large B-cell lymphoma. HNSCC – Head and neck squamous cell carcinoma. GI – Gastrointestinal. HR MDS – Higher risk myelodysplastic syndrome. HR+/HER2-mBC - Hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. FL - Follicular lymphoma. MM – Myeloid malignancies. mTNBC – Metastatic triple-negative breast cancer. mUC – Metastatic urothelial cancer. NSCLC – Non small cell lung cancer. St. – Stage. r/r – relapsed / refractory.

Upcoming Investor Events

1 FEB

Q4 & FY Results
Tuesday, 1 February 2022

17 FEB

Virology Deep Dive
Thursday, 17 February 2022

14 APR

Oncology Deep Dive
Thursday, 14 April 2022

Looking Forward: Diversified, Sustainable Growth

TODAY

- Growing HIV revenues
- Executing on oncology strategy, tracking to exceed $1B in revenue
- Nearly doubled clinical pipeline
- Key role in helping to combat COVID

2030

- **Expanding virology leadership: expect stable or growing HIV business**
- **Delivering a world-class oncology portfolio: expect to be a third of revenues**
- **Targeting 10+ transformative therapies by 2030**

GILEAD
Creating Possible

APPENDIX

Robust Pipeline with Upcoming Catalysts



55
Clinical stage programs[1]

18
NDA/BLA/MAA filings, P3 and registrational P2

11
Potential clinical stage opt-in assets

FDA approved medicines shown: Trodelvy® for 2L mTNBC, Trodelvy® for 2L mUC (accelerated approval), Yescarta® for 3L LBCL, Yescarta® R/R FL, Tecartus® for Adult ALL and MCL (accelerated approval), Veklury® for COVID-19. 1. Program count does not include potential partner opt-in programs or publicly announced planned programs. 2. Phase 1b/2 trials. 3. Conditionally approved by the European Medicines Agency (EMA) for the treatment of chronic HDV infection in adults with compensated liver disease in July 2020. 4. Includes six Phase 1 clinical stage programs and one Phase 2 clinical stage program. ALL - acute lymphocytic leukemia. AML - acute myeloid leukemia. axi-cel - axicabtagene ciloleucel. bNAb - broadly neutralizing antibody. brexu-cel - brexucabtagene autoleucel. DKD - diabetic kidney disease. DLBCL - diffuse large B cell lymphoma. dom - domvanalimab. durva - durvalumab. etruma - etrumadenant. EV - emerging viruses. FL - follicular lymphoma. HNSCC - head and neck squamous cell carcinoma. HR MDS - higher risk myelodysplastic syndrome. HR+/HER2-mBC - hormone receptor positive, human epidermal growth factor receptor 2 negative metastatic breast cancer. HTE - heavily treatment-experienced. LA - long acting. LBCL - large B cell lymphoma. mCRC - metastatic colorectal cancer. mCRPC - metastatic castrate-resistant prostate cancer. MM - multiple myeloma. mPDAC - metastatic pancreatic ductal adenocarcinoma. mTNBC - metastatic triple-negative breast cancer. mUC - metastatic urothelial carcinoma. NASH - nonalcoholic steatohepatitis. NSCLC - non small cell lung cancer. PrEP - pre-exposure prophylaxis. PSC - primary sclerosing cholangitis. quemli - quemliclustat. R/R - relapsed / refractory. TLR - toll-like receptor. VS - virologically suppressed. zim - zimberelimab.